 |
Previous Article | Next Article 
The Journal of Neuroscience, March 15, 2002, 22(6):2135-2141
Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is
Protective against Methamphetamine Neurotoxicity
Giuseppe
Battaglia1,
Francesco
Fornai1, 2,
Carla
L.
Busceti1,
Gabriella
Aloisi3,
Franca
Cerrito3,
Antonio
De
Blasi1,
Daniela
Melchiorri4, and
Ferdinando
Nicoletti1, 4
1 Instituto Neuromed Mediterraneo, Pozzilli (Isernia)
86077, Italy, 2 Department of Human Morphology and Applied
Biology, University of Pisa, Pisa 56126, Italy,
3 Department of Experimental Medicine, University of
L'Aquila, L'Aquila 67100, Italy, and 4 Department of
Human Physiology and Pharmacology, University of Roma "La
Sapienza", 00185 Rome, Italy
Methamphetamine (MA), a widely used drug of abuse, produces
oxidative damage of nigrostriatal dopaminergic terminals. We examined the effect of subtype-selective ligands of metabotropic glutamate (mGlu) receptors on MA neurotoxicity in mice. MA (5 mg/kg, i.p.; injected three times, every 2 hr) induced, 5 d later, a
substantial degeneration of striatal dopaminergic terminals associated
with reactive gliosis. MA toxicity was primarily attenuated by the coinjection of the noncompetitive mGlu5 receptor antagonists
2-methyl-6-(phenylethynyl)pyridine and
(E)-2-methyl-6-styrylpyridine both at 10 mg/kg, i.p.). In contrast, the
mGlu1 receptor antagonist
7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester (10 mg/kg, i.p.), and the mGlu2/3 receptor agonist ( )-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic acid
(1 mg/kg, i.p.), failed to affect MA toxicity. mGlu5 receptor
antagonists reduced the production of reactive oxygen species but did
not reduce the acute stimulation of dopamine release induced by MA both
in striatal synaptosomes and in the striatum of freely moving mice. We
conclude that endogenous activation of mGlu5 receptors enables the
development of MA neurotoxicity and that mGlu5 receptor antagonists are
neuroprotective without interfering with the primary mechanism of
action of MA.
Key words:
neuroprotection; methamphetamine toxicity; mGlu5
antagonists; microdialysis; striatal dopaminergic terminals; reactive
oxygen species
Copyright © 2002 Society for Neuroscience 0270-6474/02/2262135-07$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
P. H. Anborgh, C. Godin, M. Pampillo, G. K. Dhami, L. B. Dale, S. P. Cregan, R. Truant, and S. S. G. Ferguson
Inhibition of Metabotropic Glutamate Receptor Signaling by the Huntingtin-binding Protein Optineurin
J. Biol. Chem.,
October 14, 2005;
280(41):
34840 - 34848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Thiriet, X. Deng, M. Solinas, B. Ladenheim, W. Curtis, S. R. Goldberg, R. D. Palmiter, and J. L. Cadet
Neuropeptide Y Protects against Methamphetamine-Induced Neuronal Apoptosis in the Mouse Striatum
J. Neurosci.,
June 1, 2005;
25(22):
5273 - 5279.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Battaglia, C. L. Busceti, G. Molinaro, F. Biagioni, M. Storto, F. Fornai, F. Nicoletti, and V. Bruno
Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice
J. Neurosci.,
January 28, 2004;
24(4):
828 - 835.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Fornai, P. Lenzi, M. Gesi, M. Ferrucci, G. Lazzeri, C. L. Busceti, R. Ruffoli, P. Soldani, S. Ruggieri, M. G. Alessandri, et al.
Fine Structure and Biochemical Mechanisms Underlying Nigrostriatal Inclusions and Cell Death after Proteasome Inhibition
J. Neurosci.,
October 1, 2003;
23(26):
8955 - 8966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nishi, F. Liu, S. Matsuyama, M. Hamada, H. Higashi, A. C. Nairn, and P. Greengard
Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling
PNAS,
February 4, 2003;
100(3):
1322 - 1327.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|